Natics Corp.
A distressed OTC-listed entity reporting consistent losses and negative working capital with negligible recent revenue generation.
A distressed OTC-listed entity reporting consistent losses and negative working capital with negligible recent revenue generation.
An investment case exists only for contrarian investors seeking deep-value turnaround opportunities in distressed OTC securities. If management can successfully restructure liabilities and launch a viable product line, the current negative equity could represent a low-cost entry point. The stock may offer potential volatility-based returns if market sentiment shifts toward small-cap recovery plays.
Avoid this stock entirely as it lacks fundamental revenue generation with zero cost of revenue and consistent net losses over five years. The balance sheet is fundamentally broken with negative equity and current liabilities far exceeding current assets, indicating imminent liquidity crisis. There are no clear catalysts for profitability given the historical lack of income and significant debt burden.
Natics Corp. (NTCS) is a specialized entity operating within niche industrial sectors with minimal recorded revenue streams in recent periods. The company faces significant liquidity challenges characterized by substantial negative net income and operating cash flow deficits. Despite having low asset values, the firm maintains a complex capital structure with high long-term liabilities relative to its equity.
Management has struggled to generate positive operating cash flow, resulting in a net change in cash of negative seventeen thousand dollars and a retained earnings deficit exceeding eighty-two thousand dollars. The company recorded a significant loss from continuing operations while managing financing activities that added cash but could not offset operational drains. With no revenue generated in the trailing years, the firm remains dependent on external capital injections to sustain its balance sheet.
The company operates in a sector where traditional metrics like revenue growth are currently absent, likely reflecting a dormant or transitional phase within the broader industrial landscape. The OTC market often hosts such entities awaiting restructuring or niche entry, but the absence of operating data makes industry positioning difficult to ascertain. Investors must treat this as a speculative asset rather than a standard industrial play.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $1.2K | $21.9K | $16.2K |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $1.2K | $21.9K | $16.2K |
| Operating Expenses | $27.3K | $29.8K | $57.2K |
| Operating Income | $-26.1K | $-7.9K | $-41.0K |
| G&A | $27.3K | $29.8K | $57.2K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-26.1K | $-7.9K | $-41.0K |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-26.1K | $-7.9K | $-41.0K |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-26.1K | $-7.9K | $-41.0K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-26.1K | $-7.9K | $-41.0K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $20.6K | $23.7K | $6.6K |
| Long-Term Assets | $37.6K | $33.3K | $17.2K |
| Total Assets | $58.2K | $57.0K | $23.8K |
| Current Liabilities | $0 | $0 | $12.9K |
| Long-Term Liabilities | $61.4K | $66.0K | $68.4K |
| Total Liabilities | $61.4K | $66.0K | $81.3K |
| Shareholders' Equity | $-3.2K | $-8.9K | $-57.5K |
| Paid-In Capital | $22.6K | $24.7K | $24.7K |
| Retained Earnings | $-26.3K | $-34.2K | $-82.7K |
| Total L&E | $58.2K | $57.0K | $23.8K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-26.1K | $-7.9K | $-41.0K |
| Non-Cash Adjustments | $0 | $0 | $0 |
| Working Capital Changes | $1.1K | $0 | $4.3K |
| Cash from Operations | $-25.0K | $-7.9K | $-36.7K |
| Cash from Investing | $8.6K | $8.6K | $8.6K |
| Cash from Financing | $36.9K | $2.4K | $11.1K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $20.5K | $3.1K | $-17.1K |
| Beginning Cash | $100 | $20.6K | $23.7K |
| Ending Cash | $20.6K | $23.7K | $6.6K |
The financial data indicates no distinct revenue-generating segments as cost of revenue is zero for the latest period, suggesting operations may be in a wind-down, holding, or pre-revenue stage. The company's primary activity appears to be non-operational or reliant on financing activities rather than core product sales, with gross profit derived entirely from non-cost-of-revenue sources or adjustments.
The primary risk is severe insolvency due to total liabilities exceeding total assets and negative shareholder equity. Investors face the risk of permanent capital loss as operating cash flows are deeply negative and there is no revenue to service debt. The company's liquidity position is critically weak with current liabilities significantly outpacing current assets. There is a high probability of delisting or bankruptcy given the lack of profitable operations over recent years.
The company possesses no traditional competitive moats given its lack of revenue and negative shareholders' equity. Any potential advantage lies solely in its ability to secure long-term financing despite high liability burdens, which is a rare trait among distressed OTC firms.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.